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Increasing evidence shows that targeting epigenetic changes including acetylation and
deacetylation of core nucleosomal histones as well as Aurora kinases hold promise for
improving the treatment of human cancers including ovarian cancer. We investigated
whether the histone deacetylase (HDAC) inhibitor, valproic acid (VPA), and the Aurora kinase
inhibitor VE465 can have additive or synergistic effects on gynecologic cancer cells. We
tested the in vitro antitumor activity ofVPA andVE465, alone and in combination, in gyneco-
logic cancer cells and assessed potential mechanisms of action. 3-[4,5-dimethyl-2-thiazolyl]-
2,5-diphenyl-2H-tetrazolium bromide (MTT) analysis revealed that 72 h of treatment with
VPA or VE465 alone induced dose-dependent cytotoxic effects in nine gynecologic can-
cer cell lines (ovarian: 2008/C13, OVCAR3, SKOV3, and A2780; cervical: ME180 and CaSki;
endometrial: HEC-1B; and uterine sarcoma: MES-SA and MES-SA/D×5). Co-treatment with
VPA and VE465 enhanced cytotoxic effects on five of these cell lines: ovarian: 2008/C13,
A2780, and OVCAR3; endometrial: HEC-1B; and cervical: ME180. In ovarian 2008/C13 cells,
co-treatment with VPA (2 mM) and VE465 (1µM) induced more apoptosis than either VPA
or VE465 alone. Western blot analysis showed that VPA alone increased the expression of
cleaved PARP and p21 in a dose-dependent manner in 2008/C13 cells, while co-treatment
with VPA and VE465 induced more cleaved PARP than treatment with VPA or VE465 alone
did.The combined use ofVPA andVE465 enhanced cytotoxic effects in some ovarian cancer
cells, via enhanced induction of apoptosis. Targeting epigenetics with the HDAC inhibitor,
in combination with Aurora kinase inhibitors, holds promise for more effective therapy of
ovarian cancer.
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INTRODUCTION
Gynecologic cancers remain a significant cause of mortality among
American women (Jemal et al., 2007). Endometrial cancers are
the most prevalent, followed by cancers of the ovaries and the
uterine cervix. Approximately 25% of endometrial cancers (Hick-
erson, 2003), 24% of cervical cancers (Benedet et al., 2001),
and 70% of ovarian cancers (O’Malley et al., 2003) are diag-
nosed at an advanced stage. The prognosis for patients with these
advanced cancers is poor; thus, novel therapeutic strategies are
urgently needed. One strategy we investigated was the potential of
new drugs for targeting epigenetic alteration, specifically histone
deacetylase (HDAC) inhibitors, which are emerging as a new class
of potential anticancer agents.
Acetylation and deacetylation of core nucleosomal histones
play important roles in the epigenetic regulation of gene expression
(Marks et al., 2000). At least two classes of enzymes are involved in
controlling the acetylation of histones: histone acetyltransferases
(HATs) and HDACs. HDACs catalyze the removal of acetyl groups
on the amino-terminal lysine residues of histones, which generally
results in transcriptional repression (Grunstein, 1997; Mai et al.,
2005) and aberrant silencing of tumor-suppressor genes (Marks
et al., 2000). Increasing evidence shows that aberrations in HAT or
HDAC activity and in histone acetylation are linked to the devel-
opment of certain cancers (Cress and Seto, 2000; Pandolfi, 2001;
Timmermann et al., 2001; Verdin et al., 2003), including gyneco-
logic cancers (Caslini et al., 2006; Hrzenjak et al., 2006). Inhibition
of HDACs increases histone acetylation and may lead to the
restoration of transcriptionally silenced pathways or the suppres-
sion of aberrantly expressed genes (Richon and O’Brien, 2002).
Increasing numbers of HDAC inhibitors are being investigated,
and several (e.g., phenylbutyrate and suberoylanilide hydroxamic
acid) are being tested in clinical trials (Balch et al., 2004).
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Valproic acid (VPA) is a short-chain fatty acid that has been
used to treat epilepsy for 30 years. Recently, VPA has been shown
to inhibit proliferation in various cancers, including gynecologic
cancers [e.g., endometrial (Takai et al., 2004a), ovarian (Takai et al.,
2004b), and cervical cancers (de la Cruz-Hernandez et al., 2007)
and uterine sarcoma both in vivo and in vitro (Hrzenjak et al.,
2006)]. Although many mechanisms of action may underlie the
antitumor activity of VPA, many studies have suggested that mod-
ulating the epigenome by inhibiting HDACs is one of the main
actions of VPA (Gottlicher et al., 2001; Phiel et al., 2001; Blaheta
et al., 2005). VPA promotes differentiation by inhibiting HDACs,
which in turn results in the re-expression of epigenetically medi-
ated inactivated genes that are involved in cellular differentiation
and development (Gurvich et al., 2004); cell cycle arrest at the G1/S
boundary mediated by the Rb and related proteins associated with
the p53-independent induction of p21WAF1/CIP1 and the repres-
sion of cyclins; the activation of the G2/M phase by initiating a
G2-phase checkpoint; and apoptosis via the death-receptor and
mitochondrial death pathways (Facchetti et al., 2004).
Valproic acid is highly effective in suppressing the growth of
human ovarian carcinoma cells (Takai et al., 2004b). Clonogenic
assays have shown that all ovarian carcinoma cell lines are sensi-
tive to the growth-inhibitory effects of VPA. The prominent arrest
of malignant cells in the G0/G1 phase of the cell cycle is likely to
account for this effect by the increased expression of p21WAF1 and
p27KIP1, accompanied by the accumulation of acetylated histones
H3 and H4 (Takai et al., 2004b).
Targeting Aurora kinases is another potential therapeutic strat-
egy in cancer treatment (Fu et al., 2006). Three human Aurora
kinases (A,B, and C) have been cloned (Fu et al., 2006) and mapped
to chromosomes 20q13.2, 17p13.1, and 19q13.43, respectively (Li
et al., 2004; Wheatley et al., 2004). Aurora kinases play a crucial
role in controlling chromosome movement and organization dur-
ing mitosis. Aurora kinase A, a serine-threonine protein kinase, is
essential for mitotic spindle formation and accurate chromosome
segregation (Adams et al., 2001). Aurora kinase B, a chromosome
passenger protein kinase, contributes to centrosome separation,
chromosome segregation, and cytokinesis (Adams et al., 2001).
Aurora kinase C, normally found only in germ cells, is also a chro-
mosome passenger protein kinase, and is able to complement the
loss of Aurora kinase B expression under some circumstances (Li
et al., 2004; Sasai et al., 2004).
Increasing evidence shows that Aurora kinases are involved in
tumorigenesis (Fu et al., 2006). They are frequently overexpressed
and amplified in human cancers (Zhou et al., 1998), including
ovarian (Gritsko et al., 2003; Hu et al., 2005) and endometrial
cancers (Moreno-Bueno et al., 2003), and are therefore potential
targets for anticancer therapy (Naruganahalli et al., 2006; Yang
et al., 2006). A number of Aurora kinase inhibitors (e.g., VE465,
VX-680, and AT-9283) have been developed (Naruganahalli et al.,
2006), and their anticancer efficacy has been shown in preclinical
studies and phase 1 and 2 trials (Carvajal et al., 2006; Narugana-
halli et al., 2006). Treatment with these potent compounds has
resulted in the arrest of proliferation in various tumor cell lines,
including the human ovarian cancer cell line A2780, and in the
inhibition of phosphorylation of histone H3 on serine 10 (Fan-
celli et al., 2005, 2006). It is therefore likely that targeting the
enzymes involved in controlling histone modification by processes
such as acetylation and phosphorylation will provide new, bet-
ter therapeutic opportunities for ovarian cancer. However, studies
are needed to determine the cytotoxic action of Aurora kinase
inhibitors against gynecologic cancers and whetherVE465 can sen-
sitize gynecologic cancers to other antitumor drugs. In this study,
we investigated whether VE465 can enhance the cytotoxic effect of
VPA on gynecologic cancer cells and the possible mechanisms of
action involved.
MATERIALS AND METHODS
REAGENTS AND CELL CULTURE
We dissolved VPA (Sigma-Aldrich, St. Louis, MO, USA) in dis-
tilled water at a stock concentration of 1 M and filtered through
a 0.2-µm filter. We dissolved VE465 (Vertex Pharmaceuticals,
Cambridge, MA, USA) in dimethyl sulfoxide at a stock con-
centration of 10−2 M. Experiments were conducted on nine
established gynecologic cancer cell lines, including four ovarian
(three platinum-resistant: 2008/C13, OVCAR3, and SKOV3, and
one platinum-sensitive: A2780), two cervical (paclitaxel-resistant
ME180 and cisplatin-resistant CaSki; Saxena et al., 2005), one
endometrial (carboplatin-resistant HEC-1B; Smith et al., 2004),
and two uterine sarcoma (multiple-drug-resistant MES-SA and its
subline MES-SA/D×5) cell lines. The ovarian cancer cell lines were
obtained from Dr. Ralph S. Freedman (The University of Texas
MD Anderson Cancer Center, Houston, TX, USA) (Melichar et al.,
2007). The cervical and endometrial cancer cell lines and uterine
sarcoma cell lines were purchased from the American Type Culture
Collection (Manassas, VA, USA).
The ovarian cancer and uterine sarcoma cells were cultured in
RPMI 1640 medium (Gibco BRL, Grand Island, NY, USA) sup-
plemented with 10% fetal calf serum. The cervical and endome-
trial cancer cells were propagated in a medium recommended
by the American Type Culture Collection. For drug treatment,
cells were grown to about 90% fluency and detached by 0.5%
ethylenediaminetetraacetic acid (EDTA)-trypsin (Gibco BRL).
MTT ASSAY
We determined cell growth and viability using the MTT method
with an EZ4U kit (American Laboratory Products Company,
Windham, NH, USA). This assay, based on the transformation
of tetrazolium salt into colored soluble formazans as a result of
the mitochondrial activity of the viable cells, determines the per-
centage of viable cells. Cells were seeded in a 96-well plate at
4000 cells per 200µL of medium per well, and were allowed to
adhere to the plate overnight. The next day, the cells were treated
with VPA and VE465, alone and in combination, at indicated
concentrations. After treatment for 72 h, we performed the MTT
assay according to the manufacturer’s instructions. We measured
spectrophotometric absorbance of each sample at 490 nm using
a microplate reader (BioTek Instruments, Winooski, VT, USA),
performing this four times for each drug concentration in each
experiment. The percentage of cell survival was determined by the
ratio of absorbance of the sample to that of the control. The com-
bination effect of VE465 and VPA was evaluated by the method
described by Chou and Talalay (Chou, 2006, 2010) using R (ver-
sion 2.14.2) and a combination index (CI) was calculated. A CI< 1
Frontiers in Oncology | Women’s Cancer March 2013 | Volume 3 | Article 58 | 2
Li et al. Synergism between VPA and VE465
indicates a synergistic interaction, CI= 1 is additive, and CI> 1 is
antagonistic (Marth et al., 1986; Hu et al., 2002).
FLOW CYTOMETRY
We seeded 1.8× 106 cells in T25 flasks (25 m2) and allowed them
to adhere to the flask overnight. The next day, the cells were
treated with VPA and VE465, alone and in combination. After
treatment for 72 h, the cells were harvested using 0.5% EDTA-
trypsin, washed three times with ice-cold 1× phosphate-buffered
saline (PBS), and fixed with 70% ethanol at room temperature for
15 min. Cell pellets were then stained with 50µg/mL of propid-
ium iodide (Calbiochem, San Diego, CA, USA) and 20µg/mL of
ribonuclease A (Sigma-Aldrich, St. Louis, MO, USA) at room tem-
perature for 15 min. The fraction of cells that were in the sub-G1
phase was determined by using a flow cytometer (Epics XL-MCL,
Beckman Coulter, Miami, FL, USA).
TUNEL ASSAY
Cells were harvested with 0.5% EDTA-trypsin and washed with
ice-cold 1×PBS. Cytospin-prepared slides were fixed with 4%
paraformaldehyde for 20 min at room temperature, washed with
PBS, air dried, and then stored at −20˚C until use. A terminal
deoxynucleotidyl transferase-mediated dUTP nick-end labeling
(TUNEL) assay was performed by using an Apo-BRDU-IHC kit
(catalog no. AH1001, Chemicon International, Temecula, CA,
USA) according to the manufacturer’s instructions.
WESTERN BLOT ANALYSIS
For protein extraction, cells were cultured in T25 flasks and
treated as described above. After the cells were harvested, they
were washed three times with ice-cold 1×PBS and lysed with
modified radioimmunoprecipitation lysis buffer [10 mM Tris HCl
(pH 8.0), 10 mM EDTA (pH 8.0), 0.15 M NaCl, 1% NP40, and
0.5% sodium dodecyl sulfate] containing freshly added protease
inhibitor. After 30 min of incubation on ice, we cleared the lysates
by centrifugation at 12,000 rpm and 4˚C for 30 min.
We quantified protein concentrations by using the Bio-Rad
protein assay (Bio-Rad Laboratories, Hercules, CA, USA). Thirty-
five micrograms of protein were separated with 8–15% sodium
dodecyl sulfate-polyacrylamide-gradient gel (Bio-Rad Laborato-
ries), transferred to a nitrocellulose membrane (Amersham Bio-
sciences, Buckinghamshire, UK), and probed with the following
diluted antibodies: poly (ADP-ribose) polymerase (PARP; 1:800;
Promega Corporation, Madison, WI, USA), glyceraldehyde-3-
phosphate dehydrogenase, used as an internal control; 1:2,500;
Santa Cruz Biotechnology, Santa Cruz, CA, USA), and p21 (cyclin-
dependent kinase-interacting protein or WAF1/Cip1; 1:200, Santa
Cruz Biotechnology). Signals were visualized on reaction with
an enhanced chemiluminescence detection reagent (Amersham
Biosciences, Piscataway, NJ, USA).
STATISTICAL ANALYSIS
We calculated the concentrations of VPA and VE465 that inhibited
50% of the cells (IC50) using SigmaPlot 8.0 software (Systat Soft-
ware, San Jose, CA, USA). All numerical data were expressed as
mean± standard deviation. We determined the significance of the
difference between the two groups with an independent-samples
t -test. A P-value of <0.05 was considered statistically significant.
RESULTS
GROWTH INHIBITION BY VPA OR VE465 ALONE IN GYNECOLOGIC
CANCER CELLS
We tested the cytotoxic effect of VPA (0.5–16.0µM) and VE465
(0.0001–100µM) as single agent. After 72 h of treatment, cell sur-
vival was measured with an MTT assay. As shown in Figures 1
and 2, both VPA and VE465 induced dose-dependent cytotoxic
A
B
C
FIGURE 1 | Cytotoxicity in gynecologic cancer cell lines after 72h of
treatment withVPA alone. (A) Growth curves for ovarian cancer cell lines
(2008/C13, A2780, OVCAR3, and SKOV3) after treatment with VPA alone at
increasing concentrations (0.5–16 mM). (B) Growth curves for uterine and
cervical cancer cell lines (ME180, CaSki, HEC-1B, MES-SA, and
MES-SA/D×5) after treatment with VPA alone at increasing concentrations
(0.5–16 mM). (C) IC50 of VPA treatment in the nine gynecologic cancer cell
lines studied.
www.frontiersin.org March 2013 | Volume 3 | Article 58 | 3
Li et al. Synergism between VPA and VE465
A
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FIGURE 2 | Cytotoxicity in gynecologic cancer cell lines after 72h of
treatment withVE465 alone. (A) Growth curves for ovarian cancer cell
lines (2008/C13, A2780, OVCAR3, and SKOV3) after treatment with VE465
alone at increasing concentrations (0.0001–100µM). (B) Growth curves for
uterine and cervical cancer cell lines (ME180, CaSki, HEC-1B, MES-SA, and
MES-SA/D×5) after treatment with VE465 alone at increasing
concentrations (0.0001–100µM). (C) IC50 of VE465 in various gynecologic
cancer cell lines.
effects in the gynecologic cancer cell lines. The IC50 values for
VPA were between 3.0 and 10.0 mM; the values for VE465 were
between 0.1 and 58.3µM (Table 1).
ENHANCED CYTOTOXIC EFFECT OF COMBINED VPA AND VE465 ON
GYNECOLOGIC CANCER CELLS
To evaluate the combined cytotoxic effects of VPA and VE465
on the nine gynecologic cancer cell lines, we performed a 72-h
co-treatment using both agents. We used VPA at a series of concen-
trations ranging from 0.5 to 16.0 mM and VE465 at concentrations
of 0.1, 1, and 10µM for all cell lines but A2780. For the A2780 cell
line, we used three lower levels of the VE465 concentration (0.01,
Table 1 | IC50 ofVPA andVE465 after 72h of treatment in various cell
lines.
Cell line VPA (mM) VE465 (µM)
2008/C13 5.0 9.3
A2780 3.0 0.1
OVCAR3 10.0 58.3
SKOV3 8.7 52.3
HEC-1B 6.7 20.9
CaSki 4.0 27.4
ME180 5.1 12.2
MES-SA 8.5 6.4
MES-SA/D×5 6.7 11.5
VPA, valproic acid.
Table 2 | Decreased IC50 ofVPA (mM) in combined treatment with
VE465 in gynecologic cancer cells.
Treatment VPA IC50
A2780
cells
2008/C13
cells
OVCAR3
cells
HEC-1B
cells
ME180
cells
Single agent VPA 3.0 5.0 10.0 6.7 5.1
VPA+VE465 (0.01µM) 1.0 NA NA NA NA
VPA+VE465 (0.1µM) <0.5* 0.9 9.0 7.3 2.4
VPA+VE465 (1µM) <0.5* 0.6 9.8 6.5 1.9
VPA+VE465 (10µM) NA <0.5* 6.6 3.2 <0.5*
VPA, valproic acid; NA, not available.
*Even though the concentration of VPA used in combination with VE465 was as
low as 0.5mM, the growth inhibition was >50%, so the exact IC50 could not be
obtained by the program.
0.1, and 1µM) because of the cells’ high degree of sensitivity to
VE465.
We observed a synergistic effect of VPA and VE465 on 2008/C13
ovarian cancer cells. In cell line 2008/C13, IC50 decreased from
5.0 mM for VPA used alone to≤1 mM for VPA combined with var-
ious concentrations of VE465 (Table 2). When the concentration
of VPA was between 2 and 8 mM, adding 0.1, 1, or 10µM VE465
induced substantial cell growth inhibition (76.7–92.7%), which
was significantly greater than that induced by VPA or VE465 alone
(all P < 0.001). When the concentration of VPA was reduced to
<2 mM and 10µM VE465 was added, cell growth inhibition was
80.3–85.7%; when 0.1 or 1µM VE465 was added, inhibition was
40.5–58.4%. At these concentration ranges, the growth inhibition
induced by combined treatment was significantly greater than that
induced by VPA or VE465 alone (P < 0.05) (Figure 3A). Two drug
combination analysis with Chou and Talalay method indicates
that a synergistic interaction occurred between VPA and VE465
(CI< 1; Figure 3F).
With the A2780 cells, growth was inhibited 55.8–72.4% when
the concentration of VPA was 1–6 mM and the concentration
of VE465 was 0.01µM, which was significantly greater than the
growth inhibition induced by VPA or VE465 alone (all P < 0.001)
(Figure 3B). The IC50 decreased from 3.0 mM withVPA used alone
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FIGURE 3 | Cytotoxicity in gynecologic cancer cell lines: (A) 2008/C13, (B)
A2780, (C) OVCAR3, (D) HEC-1B, and (E) ME180 – after 72h of
co-treatment withVPA andVE465 at increasing concentrations. (F)
Isobologram analysis of the combined effects of VE465 and VPA in 2008C13
cells. A combination index (CI)<1 indicates a synergistic interaction, CI=1 is
additive, and CI>1 is antagonistic.
to ≤1 mM when VPA was combined with various concentrations
of VE465 (Table 2).
Similarly, greater growth inhibition was induced by combined
treatment of VPA and VE465 than by VPA or VE465 alone
in OVCAR3 (for 1–6 mM VPA and 0.1, 1, and 10µM VE465)
(Figure 3C), HEC-1B (for 2–8 mM VPA and 10µM VE465)
(Figure 3D), and ME180 cells (for 0.5–8 mM VPA and 0.1, 1, and
10µM VE465) (Figure 3E). The IC50 of VPA was decreased when
VE465 was added (Table 2).
APOPTOSIS INDUCED BY VPA AND VE465, ALONE AND IN
COMBINATION, IN 2008/C13 CELLS
We examined apoptosis induced by VPA and VE465, alone and
in combination, in the 2008/C13 cell line by using flow cytom-
etry, TUNEL, and Western blot analysis. First, flow cytometry
using propidium iodide staining showed that the percentage of
sub-G1 cells induced by VPA at 2, 4, and 8 mM was significantly
higher than that in the control (P< 0.05 or <0.01) (Figure 4A).
A 72-h treatment of 1–8 mM VPA alone or 0.01–10µM VE465
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FIGURE 4 | Flow cytometric analysis of 2008/C13 cells after 72h of treatment withVPA orVE465, alone and in combination. (A)Treatment with VPA
alone with increasing concentrations (1–8 mM). (B)Treatment with VE465 alone at increasing concentrations (0.01–10µM). (C) Co-treatment with VPA (2 mM)
and VE465 (1µM).
alone induced sub-G1 cells in 2008/C13 in a dose-dependent man-
ner (Figures 4A,B). The percentage of sub-G1 cells induced by
VE465 at 0.1 and 1µM was also significantly higher than that in
the control (P≤ 0.001) (Figure 4B). The percentage of sub-G1 cells
elicited by combined treatment of the two drugs (2 mM VPA and
1µM VE465) was 80.1%, which was 12% higher than that induced
by VE465 (64.2%) or VPA (3.7%) alone, respectively (Figure 4C).
In addition, TUNEL assays showed that VPA alone increased
apoptosis in cells with increasing concentration (Figure 5A) and
that co-treatment with VPA (2 mM) and VE465 (1µM) induced
more apoptosis than VPA or VE465 alone did (Figure 5B). Fur-
thermore, Western blot analysis showed that VPA induced the
cleaved PARP in a dose-dependent manner and that co-treatment
with VPA and VE465 induced more PARP than VPA or VE465
alone (Figures 6A,B).
p21 EXPRESSION INDUCED BY VPA AND VE465, ALONE AND IN
COMBINATION, IN 2008/C13 CELLS
Since it has been suggested that HDAC inhibitors induce increased
expression of p21 in various tumor cells including ovarian can-
cer (Richon and O’Brien, 2002; Takai et al., 2004a; Garcia-
Manero et al., 2006; Hrzenjak et al., 2006), we therefore examined
whether p21 expression could be affected by 72 h of treatment
with VPA and VE465, alone and in combination, in 2008/C13
cells. Treatment with VPA alone induced p21 expression in a
dose-dependent manner at increasing concentrations (1–8 mM).
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However, co-treatment with VPA and VE465 did not induce more
p21 expression than VPA or VE465 alone did (Figures 6C,D).
DISCUSSION
The key finding of our study is that co-treatment with VPA and
VE465 had enhanced antitumor effects in chemotherapy-resistant
gynecologic cancer cells. One possible mechanism of action is
enhanced induction of apoptosis. Growing evidence suggests that
HDAC inhibitors (such as VPA) and Aurora kinase inhibitors
(such as VE465 and VX-680) are effective agents against gyneco-
logic cancers. Targeting epigenetic targets with HDAC inhibitors
may enhance the antitumor activities of Aurora kinases inhibitors
in ovarian cancer cells. We showed here the synergistic effect of
A
B
FIGURE 5 |TUNEL analysis of apoptosis induced by 72h of treatment
withVPA alone and in combination withVE465 in 2008/C13 cells. (A)
Treatment with VPA alone at increasing concentrations of 2–8 mM. (B)
Co-treatment with VPA (2 mM) and VE465 (1µM).
treatment with VPA and VE465 on ovarian cancer cells (2008C13),
via enhanced induction of apoptosis. The precise mechanism(s)
underlying these synergistic effects require additional work.
The antitumor effect of the Aurora kinase inhibitor MK-
0457 (previously called VX-680) against gynecologic cancer was
reported in our previous study (Lin et al., 2008). MK-0457 alone
significantly reduced tumor growth and treatment of MK-0457
and docetaxel produced even greater benefit (Lin et al., 2008). We
observed that both VPA and VE465, when used alone, induced
apoptosis in a dose-dependent manner. Furthermore, we found
that co-treatment with VPA and VE465 significantly induced
apoptosis (by flow cytometry and TUNEL assay) and more cleav-
age of PARP (by Western blot analysis) than did VPA or VE465
alone.
p21 is a cyclin-dependent kinase inhibitor that binds to cyclin-
dependent kinase complexes, decreases kinase activity, and may
play an important role in G0–G1 accumulation (Li et al., 2005).
Studies have shown that HDAC inhibitors induce increased expres-
sion of p21 in various tumor cells (Richon and O’Brien, 2002;
Takai et al., 2004a; Garcia-Manero et al., 2006; Hrzenjak et al.,
2006), which then causes cell cycle arrest. In ovarian cancer, p21
was induced by suberoylanilide hydroxamic acid, another HDAC
inhibitor (Takai et al., 2004b). We found that VPA increases p21
expression in a dose-dependent manner, suggesting that p21 is
involved in the antitumor activity of VPA in ovarian cancer cells.
However, we observed no significant increase in p21 expression
in the cells treated with the combination of VE465 and VPA. This
is inconsistent with another study in which the increased expres-
sion of p21WAF1 and p27KIP1, accompanied by the accumulation
of acetylated histones H3 and H4, appeared to induce the promi-
nent arrest of malignant cells in the G0/G1 phase of the cell cycle
(Takai et al., 2004b).
Moreover, our previous study indicated that VE465 synergisti-
cally enhanced cytotoxic effects of carboplatin in ovarian cancer
A B
C D
FIGURE 6 |Western blot and image analysis of cleaved PARP and P21
expression induced by 72h of treatment withVPA alone and in
combination withVE465 in 2008/C13 cells. (A,B)Treatment of VPA alone
induced cleaved PARP and P21 expression in a dose-dependent manner.
(C,D) Co-treatment with VPA and VE465 induced more expression of cleaved
PARP, but not of P21, than treatment with VPA or VE465 alone.
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cells through induction of apoptosis and downregulation of phos-
phorylated histone 3. Whether the synergistic or parallel pathways
of histone 3 phosphorylation and acetylation played a critical role
in the induction of genes was not clear, however. It is plausible
to hypothesize that this synergy might be explained by several
causes, such as upregulating genes involved in the cell cycle (p21
and p27), the stabilization of p53, and the induction of apoptosis
and balances between histone 3 phosphorylation and acetylation
in controlling gene transcriptional activation. The effect of the
interaction of H3 acetylation and phosphorylation on p21 expres-
sion in ovarian cancer cells treated with this combination needs to
be further investigated.
In summary, combined VPA and VE465 enhanced cytotoxic
effect on some gynecologic cancer cells. The possible mechanisms
may be achieved via induction of apoptosis. Further studies are
warranted to investigate the in vivo antitumor effect of these two
drugs in gynecologic cancers. Synergistic activity in cell culture
could translate into substantial clinical antitumor activity with
the levels of each drug that can be attained clinically.
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